- $192,290.00 -192,290.00/year*
196 Town Office Rd
VYNDAQEL (tafamidis meglumine) received early FDA approval in May for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular-related mortality and hospitalizations. VYNDAQEL is the first-in-class therapy and the first FDA-approved treatment for ATTR-CM, a life threatening, highly underdiagnosed condition. There are two types of ATTR-CM: wild type (wt), and hereditary (h). hATTR-CM has clinical and demographic features that mak
* The salary listed in the header is an estimate based on salary data for similar jobs in the same area. Salary or compensation data found in the job description is accurate.
Loading some great jobs for you...